IPO - ENDRA Life Sciences Inc.

Form Type: 8-K

Filing Date: 2025-07-09

Corporate Action: Ipo

Type: New

Accession Number: 000165495425007893

Filing Summary: On July 9, 2025, ENDRA Life Sciences Inc. filed a Registration Statement on Form S-1 for a public offering of shares of the Company’s common stock and related warrants. The filing includes preliminary unaudited estimated financial results for the fiscal quarter ended June 30, 2025, as detailed in the attached Prospectus (Exhibit 99.1). This information is being furnished as part of the Form 8-K and is not intended to be deemed 'filed' under the Securities Exchange Act of 1934.

Form Type: S-1

Filing Date: 2025-07-09

Corporate Action: Ipo

Type: New

Accession Number: 000165495425007870

Filing Summary: ENDRA Life Sciences Inc. has filed a Registration Statement with the SEC for an initial public offering (IPO) of 15,700,000 shares of common stock, alongside Pre-Funded and Underwriter Warrants. The company aims to raise capital to develop its unique Thermo-Acoustic Enhanced Ultrasound (TAEUS) technology, which measures liver fat and targets the metabolic disease market. The document includes information on the company's renewed strategy focusing on new markets, business model changes, risk factors involved, and details about underwriter engagement with Lucid Capital Markets, LLC. The estimated initial offering price is set at $8.30 per share, contingent on final negotiations with the underwriters. Furthermore, the offering includes provisions for potential overallotment options and notes the lack of an established market for Pre-Funded Warrants. The offering is also subjected to the usual risks and regulatory compliance requirements associated with IPOs.

Form Type: DRS

Filing Date: 2025-05-09

Corporate Action: Ipo

Type: New

Accession Number: 000165495425005304

Filing Summary: ENDRA Life Sciences Inc. has submitted a confidential Draft Registration Statement on Form S-1 as part of the process to conduct an initial public offering (IPO) of shares of its common stock. The registration statement has not been publicly filed and remains confidential. The company aims to raise capital through the offering, intended to support the commercialization of its next-generation enhanced ultrasound technology platform, Thermo-Acoustic Enhanced Ultrasound (TAEUS®), with the primary application focusing on the assessment of liver fat content. ENDRA outlines a strategic shift in its business model aimed at becoming a leading provider of biomarker solutions for metabolic diseases, specifically targeting pharmaceutical companies and clinical research organizations. The company will implement a subscription-based revenue model alongside its traditional sales strategy. The document highlights significant risks associated with the business, including the need for additional capital, regulatory challenges, and market acceptance of its technology. Furthermore, ENDRA's stock underwent reverse splits in 2024 to comply with Nasdaq's minimum listing requirements. The updated offering details include potential underwriter agreements and negotiations concerning pricing.